China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL

China Medical System Holdings Limited is pleased to announce that according to a notice issued by National Healthcare Security Administration and the Ministry of Human Resources and Social Security of the People’s Republic of China on 13 December 2023, innovative drugs Diazepam Nasal Spray (VALTOCO) and Tildrakizumab Injection (ILUMETRI) and rare disease drug Tetrabenazine Tablets have been newly included in category B of China’s National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2023 Version) (the “National Reimbursement Drug List”) and Recombinant Human Brain Natriuretic Peptide for Injection (XinHuoSu) has continued to be included in category B of the National Reimbursement Drug List, which shall be officially implemented from 1 January 2024. In addition, innovative drug Methotrexate Injection (Metoject) indicated for psoriasis approved in March 2023 has been included in category A of the National Reimbursement Drug List.

Basic Information of the Products

VALTOCO (Diazepam Nasal Spray)

VALTOCO has been approved for marketing in China in June 2023. It is the first nasal spray formulation of diazepam in China and the first drug approved in China for the treatment of seizure clusters. VALTOCO is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.

VALTOCO is a proprietary formulation of diazepam administered through the nasal mucosa with high bioavailability, outstanding absorbability, tolerance and reliability. VALTOCO has a unique combination of Vitamin E-based solvents and Intravail® absorption enhancer. Intravail® transmucosal absorption enhancement technology enables the non-invasive delivery of a broad range of proteins, peptides and small-molecule drugs. VALTOCO is administered intranasally. Under prescription from a doctor and guidance from medical staff, VALTOCO can be administered anytime and anywhere with a rapid onset of action. It has the differentiated advantages of seizure rescue and convenient administration, meeting the current clinical need of acute treatment of domestic epilepsy patients with cluster seizures.

CMS was assigned the relevant assets of VALTOCO for the exclusive use of such assets in the Territory (mainland China, Hong Kong, Macau, Taiwan, and Singapore) from A&B (HK) Company Limited through an asset assignment and exclusive license agreement with Neurelis, Inc., a U.S. company.

ILUMETRI (Tildrakizumab Injection)

ILUMETRI has been approved for marketing in China in May 2023. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMETRI is a humanized lgG1/κ monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines.

The results of the extended study of Phase III clinical trial in China demonstrated that the primary efficacy assessment indicator PASI 75 response rate continued to increase over treatment time. The PASI 75 response rate reached a high level after 28 weeks of treatment with ILUMETRI and maintained at 91.3% at week 52, and ILUMETRI showed good long-term safety and tolerance. ILUMETRI only requires 4 administrations per year over maintenance period, which may result in higher patient compliance.

CMS obtained an exclusive license for ILUMETRI from Sun Pharmaceutical Industries Ltd. in June 2019.

Tetrabenazine Tablets

Tetrabenazine Tablets has been approved for marketing in China in May 2023. It is indicated for the treatment of Huntington’s disease. Tetrabenazine tablets, as a first-line drug for Huntington’s disease, is expected to provide another more accessible and affordable drug option for patients with the rare disease.

CMS obtained an exclusive license for Tetrabenazine Tablets from Sun Pharmaceutical Industries Ltd. in August 2019.

XinHuoSu (Recombinant Human Brain Natriuretic Peptide for Injection)

XinHuoSu is the only Recombinant Human Brain Natriuretic Peptide (rhBNP) medicine available in the Chinese market and is indicated for the treatment of acute decompensated heart failure. XinHuoSu can quickly ease the symptoms and signs of heart failure in patients with heart failure and improve the quality of life of patients. It has been recommended by multiple authoritative guidelines and consensus.

XinHuoSu is owned and manufactured by a wholly-owned subsidiary of Tibet Rhodiola Pharmaceutical Holding Company (a company listed on the Shanghai Stock Exchange with stock code: 600211) (the “Tibet Pharmaceutical”). CMS holds approximately 37.36% of the shares of Tibet Pharmaceutical. CMS obtained the exclusive sale and distribution right of XinHuoSu from Tibet Pharmaceutical in March 2008.

Impacts on the Company

CMS actively responds to national policies to promote innovative products to be included in the National Reimbursement Drug List. Up to now, three innovative drugs that have been approved for marketing (VALTOCO, ILUMETRI and Metoject) have all been included in the National Reimbursement Drug List, further improving the accessibility and affordability of the drugs and allowing innovative products to benefit more patients. At the same time, the new/continued inclusion of the four products in the National Reimbursement Drug List will be conducive to promoting the market coverage of the products and building professional brand power, and will have a positive effect on CMS’s business development.

Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations

Topic: Press release summary

Japan – Mazda Included in MSCI Japan ESG Select Leaders Index

Mazda Motor Corporation has been included in the MSCI Japan ESG Select Leaders Index, a major ESG investment index. This makes Mazda a constituent of all five ESG indices for Japanese stocks (listed below) that are adopted by the Government Pension Investment Fund, one of the world�s largest pension reserve fund managers.

MSCI Japan ESG Select Leaders Index
MSCI Japan Empowering Women Index (WIN)
FTSE Blossom Japan Index
FTSE Blossom Japan Sector Relative Index
S&P/JPX Carbon Efficient Index

Members of the MSCI Japan ESG Select Leaders Index are selected by major U.S. financial services company Morgan Stanley Capital International. Listed Japanese companies are assessed in their respective industries and only those with relatively high ESG ratings are included in the index.

Mazda strives to grow as a company and to continuously challenge ourselves to realize our corporate vision of brightening people�s lives, existing sustainably with the earth and society.
Mazda Sustainability website: External Evaluations:

Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Japan – Mazda Included in Dow Jones Sustainability Asia Pacific Index for Fifth Year Running

Mazda Motor Corporation has been included in the Dow Jones Sustainability Indices’ Asia Pacific Index for the fifth year running.

The Dow Jones Sustainability Indices are among the longest-running(1) ESG investment indices(2) in the world. Corporations are assessed annually in the areas of environmental initiatives, social contribution, human resource development, corporate governance and compliance, and only those with outstanding sustainability performance in their industry are included.

Mazda was selected on the basis of a survey questionnaire and a comprehensive review of the company’s Sustainability Report, Annual Report and official website that highly evaluated Mazda’s CSR initiatives and information disclosure practices. Mazda was one of 77 Japanese companies and three automotive companies chosen from among approximately 600 major corporations assessed for inclusion in the DJSI Asia Pacific Index this year.

Mazda will continue to prioritize CSR in all initiatives and contribute to the development of a sustainable society. The company aims to build a special bond with customers and envisions a world in which cars exist in harmony with the earth, people and society.

For more information:
Mazda Sustainability Report(3)
Annual Report

(1) Dow Jones Sustainability Indices were established in 1999 by S&P Dow Jones Indices and RobecoSAM.
(2) Investment indices based on performance in the areas of environment, social contribution and governance (ESG).
(3) The 2021 edition will be published within Fiscal year ending March 2022.

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Joy Spreader Included in the MSCI China Small Cap Index

On May 12th , Joy Spreader (06988.HK), a Hong Kong-listed company, announced that the Company is incorporated into the MSCI China Small Cap Index, with effect upon the closure of the market on May 27, 2021.

It is reported that the MSCI China Small Cap Index is one of the China market indices launched by Morgan Stanley Capital International (MSCI), which aims to measure the performance of the small cap segment in China’s stock market, covering PRC companies with excellent operating results and development potential. It is an important index for global institutional investors to evaluate their investment portfolios.

Joy Spreader is a leading MarTech company engaging in mobile new media performance-based marketing and marketing SaaS services in the PRC. It has achieved outstanding performance for years and has received considerable attention in the Hong Kong stock market since its listing.

According to the financial report, the revenue of Joy Spreader was HK$262 million, HK$538 million and HK$924 million from 2018 to 2020, respectively, and the earnings (net profit) during the year were HK$45 million, HK$77 million and HK$139 million, respectively. Joy Spreader’s performance has maintained rapid growth.

The Company’s board of directors believes that the inclusion of the MSCI China Small Cap Index shows the recognition of the Company’s performance and value by the capital market. It is expected that the inclusion will enhance the confidence of capital market and investors to the Company and increase the liquidity of the Company’s shares. At the same time, the inclusion will raise the Company’s profile and boost the Company’s business and cooperation.

Topic: Press release summary